Quantum Sensors market is projected to grow at a CAGR of 15.3% by 2034: Visiongain
June 13, 2024 06:04 ET
|
Visiongain Reports Ltd
Visiongain has published a new report entitled Quantum Sensors Market Report 2024-2034: Forecasts by Component (Quantum Dots, Quantum Cascade Lasers, Other), by Application (Aerospace & Defence,...
NIRI Twin Cities Chapter Elects 2024-2025 Board of Directors
June 07, 2024 09:30 ET
|
NIRI Twin Cities Chapter
The Twin Cities Chapter of the National Investor Relations Institute today announced the election of its officers and directors for the next program year
CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director
June 04, 2024 16:05 ET
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director
TruGolf Launches National Franchising Initiative with Regional Developer Model
June 04, 2024 09:00 ET
|
TruGolf Holdings, Inc.
Leading Seller and Distributor of Golf Simulator Software and Hardware Launches TruGolf Links Franchising and Aggressive Growth Strategy with Regional Developer Model SALT LAKE CITY, June 04,...
Apogee Minerals Announces Appointment of New Director
June 03, 2024 08:00 ET
|
Apogee Minerals Ltd.
Vancouver, British Columbia, June 03, 2024 (GLOBE NEWSWIRE) -- Apogee Minerals Ltd. (“Apogee” or the “Company”) (TSXV: APMI) is pleased to announce the appointment of Mr. Nicholas Coltura as a...
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
May 28, 2024 07:30 ET
|
Apogee Therapeutics, LLC
SAN FRANCISCO and WALTHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the...
Apogee Therapeutics to Participate in Upcoming June Investor Conferences
May 23, 2024 07:30 ET
|
Apogee Therapeutics, LLC
SAN FRANCISCO and WALTHAM, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the...
Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
May 15, 2024 16:01 ET
|
Apogee Therapeutics, LLC
Interim clinical data from APG777 Phase 1 healthy volunteers study exceeded all trial objectives and achieved a half-life of approximately 75 days with a potentially best-in-class profile 16-week...
TruGolf Appoints Doug Bybee as Chief Revenue Officer
May 14, 2024 09:00 ET
|
TruGolf Holdings, Inc.
SALT LAKE CITY, May 14, 2024 (GLOBE NEWSWIRE) -- TruGolf Holdings, Inc. (Nasdaq: TRUG) ("TruGolf”), among the leading sellers and distributors of golf simulator software and hardware, is today...
Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results
May 13, 2024 07:00 ET
|
Apogee Therapeutics, LLC
Initiated a Phase 2 clinical trial of APG777, a subcutaneous half-life extended monoclonal antibody targeting IL-13, in patients with moderate-to-severe atopic dermatitis, with 16-week...